AKRO

Akero Therapeutics, Inc.

19.47 USD
+1.15 (+6.28%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Akero Therapeutics, Inc. stock is down -0.76% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 2 CALLs, 8 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Apr 16:46 17 Jan, 2025 30.00 CALL 200 90
25 Apr 13:35 17 May, 2024 20.00 PUT 200 1235
25 Apr 13:39 17 May, 2024 27.50 PUT 36 828
25 Apr 13:39 17 May, 2024 27.50 PUT 71 828
25 Apr 13:42 17 May, 2024 27.50 PUT 77 828
25 Apr 13:42 17 May, 2024 27.50 PUT 39 828
25 Apr 13:42 17 May, 2024 27.50 PUT 30 828
26 Apr 18:46 16 Jan, 2026 30.00 CALL 54 67
06 May 17:17 15 Nov, 2024 22.50 PUT 74 2
23 May 17:10 21 Jun, 2024 17.50 PUT 366 202

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins.

  • Evercore Partners
    Wed May 15, 09:16
    buy
    confirm
  • Canaccord Genuity
    Mon May 13, 12:34
    buy
    confirm
  • HC Wainwright & Co.
    Mon May 13, 06:43
    buy
    confirm